Johnson & Johnson - Index

Johnson & Johnson - report - Index

11. Segments of Business (1) and Geographic Areas
Sales to Customers (2)
____________________________________
(Dollars in Millions) 2007 2006 2005
Consumer — United States $ 6,408 4,573 4,405
International 8,085 5,201 4,691
Total 14,493 9,774 9,096
Pharmaceutical — United States 15,603 15,092 14,478
International 9,263 8,175 7,844
Total 24,866 23,267 22,322
Medical Devices and Diagnostics — United States 10,433 10,110 9,494
International 11,303 10,173 9,602
Total 21,736 20,283 19,096
Worldwide total $61,095 53,324 50,514
Operating Profit Identifiable Assets
____________________________________ ____________________________________
(Dollars in Millions) 2007 (5) 2006 (6) 2005 (7) 2007 2006 2005
Consumer $ 2,277 1,374 1,592 $26,550 25,380 6,275
Pharmaceutical 6,540 6,894 6,365 19,780 18,799 16,091
Medical Devices and Diagnostics 4,846 6,126 5,240 19,978 18,601 16,540
Total 13,663 14,394 13,197 66,308 62,780 38,906
Less: (Income)/Expenses not allocated to segments (3) 380 (193) 81
General corporate (4) 14,646 7,776 19,958
Worldwide total $13,283 14,587 13,116 $80,954 70,556 58,864
Additions to Property, Depreciation and
Plant & Equipment Amortization
____________________________________ ____________________________________
(Dollars in Millions) 2007 2006 2005 2007 2006 2005
Consumer $ 504 344 321 $ 472 255 232
Pharmaceutical 1,137 1,246 1,388 1,033 929 918
Medical Devices and Diagnostics 919 823 785 1,080 861 821
Segments total 2,560 2,413 2,494 2,585 2,045 1,971
General corporate 382 253 138 192 132 122
Worldwide total $2,942 2,666 2,632 $2,777 2,177 2,093
Sales to Customers (2) Long-Lived Assets (8)
____________________________________ ____________________________________
(Dollars in Millions) 2007 2006 2005 2007 2006 2005
United States $32,444 29,775 28,377 $21,685 22,432 15,355
Europe 15,644 12,786 12,187 15,578 14,443 5,646
Western Hemisphere excluding U.S. 4,681 3,542 3,087 3,722 3,108 957
Asia-Pacific, Africa 8,326 7,221 6,863 1,261 1,206 596
Segments total 61,095 53,324 50,514 42,246 41,189 22,554
General corporate 702 543 451
Other non long-lived assets 38,006 28,824 35,859
Worldwide total $61,095 53,324 50,514 $80,954 70,556 58,864
(1) See Note 1 for a description of the segments in which the Company operates.
(2) Export sales and intersegment sales are not significant. In 2007, 2006 and 2005, the Company did not have a customer that represented 10% of total revenues.
(3) Amounts not allocated to segments include interest (income)/expense, minority interest and general corporate (income)/expense.
(4) General corporate includes cash and marketable securities.
(5) Includes $745 million of restructuring expense, comprised of $15 million, $429 million, and $301 million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics
segments, respectively. The Medical Devices and Diagnostics segment Includes $807 million of In-Process Research and Development (IPR&D). The Pharmaceutical segment also
includes $678 million for the write-down of the NATRECOR® intangible asset .
(6) Includes $320 million and $239 million of IPR&D for the Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment
also includes the Guidant acquisition agreement termination fee, less associated expenses, of $622 million.
(7) Includes $302 million and $60 million of IPR&D for the Pharmaceutical and Medical Devices and Diagnostics segments, respectively.
(8) Long-lived assets include property, plant and equipment, net for 2007, 2006 and 2005 of $14,185, $13,044 and $10,830, respectively, and intangible assets, net for 2007, 2006
and 2005 of $28,763, $28,688 and $12,175, respectively.
NOTES TO CONSOLIDA TED FINANCIAL ST A TEMENTS 59